JPMorgan lowered the firm’s price target on BioNTech (BNTX) to $122 from $124 and keeps a Neutral rating on the shares. The firm updated estimates for the company and refreshed its script trend analysis for the COVID vaccines. While the start of the U.S. vaccination season was pulled forward compared to 2023, the overall the peak is lower based on COVID vaccine trends up to mid-November, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- Trump Trade: Trump Media considers developing crypto payment service
- Trump expected to pick Martin Makary to head FDA, Reuters reports
- Walmart higher, Lowe’s lower after earnings: Morning Buzz
- Workday initiated, Kraft Heinz downgraded: Wall Street’s top analyst calls
- BioNTech upgraded to Outperform from In Line at Evercore ISI